GlaxoSmithKline sales contract by 1.0 per cent in 2012

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has posted a 1.0 per cent decline in its annual turnover for the year ending December 31st, according to a financial update issued by the company on Wednesday.

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has posted a 1.0 per cent decline in its annual turnover for the year ending December 31st, according to a financial update issued by the company on Wednesday.

Turnover contracted to £26,431m with the adverse impact to performance in 2012 being blamed on weaker than expected sales from GSK's European business.

European sales lower than expectedGroup turnover by geographic region contracted 7.0% to £7,320m at constant exchange rates, while sales slid 4.0% to £8,446m in the US.

In Japan, GSK's sales also dropped by 5.0% to £2,225m. These reductions in sales were partially offset by growth in the Emerging Markets region.

Emerging markets potentialGSK reported that total sales in emerging markets currently account for 26% of its business and the group reported sales there had risen by 10% over the year.

The group delivered core earnings per share of 112.7p in 2012 and cash inflow from operating activities of £7.0bn before legal settlements.

Pharmaceuticals turnover fell 2.0%, which GSK said reflected increased pressure from austerity measures in Europe.

Vaccines turnover declined 2.0%, reflecting the impact of lower sales of Cervarix in Japan - £132m worth of Cervarix was sold in 2012, compared to £344m in 2011 following the completion of the 2011 HPV vaccination catch-up programme.

R&D: 15 products potentilly launchable in coming three yearsGSK reported that "significant progress" had been made in its research and development department, stating that the group had six new products under regulatory review. It said that over the next 15 years, GSK would have the potential to launch around 15 new products globally.

Analysts' predictions: Turnover beats expectationsOverall, GSK's results exceeded the expectations of analysts at Credit Suisse.

Analysts at Credit Suisse forecast in January that GlaxoSmithKline would report £26,358m in group sales - slightly less than the £26,431m which was reported on Wednesday.

The financial services company had also forecast a core earnings per share value not diluted at 111.7p. GSK's results showed a core earnings per share of 112.7p.

GSK's share price was down 0.21% to 1,439.50p at 13:08 on Wednesday afternoon.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Inflation is the easiest way out of this – just don’t expect politicians to admit it
Inflation

Inflation is the easiest way out of this – just don’t expect politicians to admit it

The UK government borrowed £34.1bn in December, a record amount for that month. Britain's debt pile now amounts to 100% of GDP. How are we going to pa…
22 Jan 2021
The best investment trusts to buy for 2021
Investment trusts

The best investment trusts to buy for 2021

Sectors ranging from emerging markets to student accommodation look poised to do well this year, says David Stevenson, as he picks the best investment…
19 Jan 2021